Activist Investors Bid $2.25 Per Share to Take Over SEER
Activist investors offer to buy Seer for $2.25/share cash + CVR, criticize CEO, and push board to respond by Apr 22.
Already have an account? Sign in.
Activist investors offer to buy Seer for $2.25/share cash + CVR, criticize CEO, and push board to respond by Apr 22.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.